CAR T-Cell Therapy: A Healthcare Professional's Guide to Yescarta (KTE-C19) Studies
Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Oct 1, 2018.
Sources
- Leukemia and Lymphoma Society. Chimeric Antigen Receptor (CAR) T-Cell Therapy. Accessed February 13, 2018 at http://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy
- CAR T-Cell Therapy: Engineering Patients’ Immune Cells to Treat Their Cancers. National Cancer Institute (NCI). Accessed October 24, 2017 at https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
- Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267-76. Accessed October 24, 2017 at https://www.ncbi.nlm.nih.gov/pubmed/23546520
- Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549. Accessed October 24, 2017 at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322257/
- Kite Pharma. Pipeline. Accessed October 24, 2017 at kitepharma.com/our-research/pipeline/
- Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory aggressive diffuse large B-cell lymphoma (DLBCL): results from the international SCHOLAR-1 study. Presented at: the 2016 American Society of Clinical Oncology Annual Meeting; Chicago, Illinois; June 3-7, 2016. Abstract 7516.
- Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL). Dec. 7, 2015. News Release. Kite Pharma.
- Leukemia and Lymphoma Society. Chimeric Antigen Receptor (CAR) T-Cell Therapy. Accessed April 25, 2017 at https://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy
- KTE-C19 Approval Status. FDA Status. Drugs.com. Accessed October 24, 2017 at /history/yescarta.html
- What is HLH? Cincinnati Children's. Accessed October 24, 2017 at https://www.cincinnatichildrens.org/service/h/hlh/about
- Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL). Clinical Trials. Drugs.com. March 31, 2017. Accessed October 24, 2017 at https://www.drugs.com/nda/kte_c19_170331.html
- Neelapu S. An Interim Analysis of the ZUMA-1 Study of KTE-C19 in Refractory, Aggressive Non-Hodgkin Lymphoma. Clinical Advances in Hematology & Oncology. Vol. Volume 15, Issue 2, February 2017. Accessed October 24, 2017 at http://www.hematologyandoncology.net/index.php/archives/february-2017/an-interim-analysis-of-the-zuma-1-study-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma/
- ClinicalTrials.gov. A multi-center study evaluating KTE-C19 in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (ZUMA-4). https://clinicaltrials.gov/ct2/show/NCT02625480. Identifier: NCT02625480. Accessed October 24, 2017.
- ClinicalTrials.gov. A phase 2 multicenter study evaluating subjects with relapsed/refractory mantle cell lymphoma (ZUMA-2). https://clinicaltrials.gov/ct2/show/NCT02601313. Identifier: NCT02601313. Accessed April 23, 2017.
- ClinicalTrials.gov. A study evaluating KTE-C19 in adult subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) (ZUMA-3). https://clinicaltrials.gov/ct2/show/NCT02614066. Identifier: NCT02614066. Accessed October 24, 2017.
- ClinicalTrials.gov. A study evaluating KTE-C19 in combination with atezolizumab in subjects with refractory diffuse large B-cell lymphoma (DLBCL) (ZUMA-6). https://clinicaltrials.gov/ct2/show/NCT02926833. Identifier: NCT02926833. Accessed October 24, 2017.
- Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T-cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285-95. Accessed October 24, 2017 at http://www.cell.com/molecular-therapy-family/molecular-therapy/references/S1525-0016(16)45375-X
- Wang M, Locke F, Siddiqi T, et al. ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL). Ann Oncol (2016) 27 (suppl_6): 945TiP. Accessed October 24, 2017 at https://academic.oup.com/annonc/article-abstract/27/suppl_6/945TiP/2799682/ZUMA-2-A-phase-2-multi-center-study-evaluating-the?redirectedFrom=fulltext
- Adam B. Kite Pharma’s CAR-T drug begins LA hospital trial in children. FierceBiotech. May 2, 2016. Accessed October 24, 2017 at http://www.fiercebiotech.com/biotech/kite-pharma-s-cart-drug-begins-la-hospital-trial-children
- American Pharmacy News. ZUMA-6 clinical trial enrolls first patient. Accessed October 24, 2017 at http://americanpharmacynews.com/stories/511017051-zuma-6-clinical-trial-enrolls-first-patient
- Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory aggressive diffuse large B-cell lymphoma (DLBCL): results from the international SCHOLAR-1 study. Presented at: the 2016 American Society of Clinical Oncology Annual Meeting; Chicago, Illinois; June 3-7, 2016. Abstract 7516.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.